Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Rury Holman has congratulated the ACE team on reaching the 6,500 randomised target.

The aim of the Acarbose Cardiovascular Evaluation (ACE) clinical trial is to establish if a drug called acarbose can prevent people with coronary heart disease and impaired glucose tolerance (IGT) from experiencing, or dying from, further heart attacks and strokes.  The ACE Trial is also looking to see if acarbose, which reduces blood glucose following a meal, can prevent or delay people progressing from IGT to type 2 diabetes.  This is a phase IV multinational trial which began in 2008.  It is being conducted in around 150 hospitals in mainland China and Hong Kong.

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk